Drug Profile


Alternative Names: LSN-2322600; LY-2228820; LY2228820 dimesylate; p38 MAP inh; Ralimetinib mesylate

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Centre Jean Perrin; Eli Lilly
  • Class 2 ring heterocyclic compounds; Antineoplastics; Fluorobenzenes; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I/II Glioblastoma
  • Phase I Colorectal cancer; Non-small cell lung cancer
  • No development reported Lymphoma; Multiple myeloma; Solid tumours

Most Recent Events

  • 15 May 2017 Eli Lilly completes a phase I trial in Non-small cell lung cancer and Colorectal cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Germany, USA (IV) (NCT02860780)
  • 05 Aug 2016 Eli Lilly plans a phase I trial for Cancer, including Colorectal cancer and Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA and Germany (PO) (NCT02860780)
  • 01 Aug 2016 Phase-I clinical trials in Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in Germany, USA (PO) (NCT02860780)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top